{"title":"表面活性剂联合美洛昔康自纳米乳化给药系统:配方及体外释放模型","authors":"Salsabila Ayundiva Putri, Lina Winarti","doi":"10.46542/pe.2023.234.7175","DOIUrl":null,"url":null,"abstract":"Background: Meloxicam has low water solubility, which affects the dissolution and level of absorption.\nObjective: The study aimed to develop a self-nano-emulsifying drug delivery system (SNEDDS) based on a non-ionic surfactant combination and evaluate the release kinetics model using the DDsolver program.\nMethods: Oil, surfactant, and co-surfactant were selected based on the solubility of meloxicam.\nResults: The best formula showed that 10% of castor oil, 70% of surfactant (tween 80: chromophore RH 40 in 1:1), and 20% of PEG 400 could develop SNEDDS with the 99.84±0.04% percentage of transmittance, 15.47±0.72 sec emulsifying time, and below 50 nm droplet size. The optimised formula is also stable and resistant to various dilutions and pH The dissolution efficiency (DE0-60) reveals a 5.27-fold increase compared to non-SNEDDS meloxicam. Meloxicam follows Korsmeyer-Peppas release kinetics, while meloxicam SNEDDS follows the Hixon-Crowell model.\nConclusion: The best formula of SNEDDS consisting of a surfactant combination generate improvement in vitro dissolution of meloxicam.","PeriodicalId":19944,"journal":{"name":"Pharmacy Education","volume":"47 1","pages":"0"},"PeriodicalIF":0.5000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meloxicam self-nano-emulsifying drug delivery system with surfactants combination: Formulation and in vitro release model\",\"authors\":\"Salsabila Ayundiva Putri, Lina Winarti\",\"doi\":\"10.46542/pe.2023.234.7175\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Meloxicam has low water solubility, which affects the dissolution and level of absorption.\\nObjective: The study aimed to develop a self-nano-emulsifying drug delivery system (SNEDDS) based on a non-ionic surfactant combination and evaluate the release kinetics model using the DDsolver program.\\nMethods: Oil, surfactant, and co-surfactant were selected based on the solubility of meloxicam.\\nResults: The best formula showed that 10% of castor oil, 70% of surfactant (tween 80: chromophore RH 40 in 1:1), and 20% of PEG 400 could develop SNEDDS with the 99.84±0.04% percentage of transmittance, 15.47±0.72 sec emulsifying time, and below 50 nm droplet size. The optimised formula is also stable and resistant to various dilutions and pH The dissolution efficiency (DE0-60) reveals a 5.27-fold increase compared to non-SNEDDS meloxicam. Meloxicam follows Korsmeyer-Peppas release kinetics, while meloxicam SNEDDS follows the Hixon-Crowell model.\\nConclusion: The best formula of SNEDDS consisting of a surfactant combination generate improvement in vitro dissolution of meloxicam.\",\"PeriodicalId\":19944,\"journal\":{\"name\":\"Pharmacy Education\",\"volume\":\"47 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2023-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy Education\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.46542/pe.2023.234.7175\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"EDUCATION, SCIENTIFIC DISCIPLINES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy Education","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46542/pe.2023.234.7175","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}
Meloxicam self-nano-emulsifying drug delivery system with surfactants combination: Formulation and in vitro release model
Background: Meloxicam has low water solubility, which affects the dissolution and level of absorption.
Objective: The study aimed to develop a self-nano-emulsifying drug delivery system (SNEDDS) based on a non-ionic surfactant combination and evaluate the release kinetics model using the DDsolver program.
Methods: Oil, surfactant, and co-surfactant were selected based on the solubility of meloxicam.
Results: The best formula showed that 10% of castor oil, 70% of surfactant (tween 80: chromophore RH 40 in 1:1), and 20% of PEG 400 could develop SNEDDS with the 99.84±0.04% percentage of transmittance, 15.47±0.72 sec emulsifying time, and below 50 nm droplet size. The optimised formula is also stable and resistant to various dilutions and pH The dissolution efficiency (DE0-60) reveals a 5.27-fold increase compared to non-SNEDDS meloxicam. Meloxicam follows Korsmeyer-Peppas release kinetics, while meloxicam SNEDDS follows the Hixon-Crowell model.
Conclusion: The best formula of SNEDDS consisting of a surfactant combination generate improvement in vitro dissolution of meloxicam.
期刊介绍:
Pharmacy Education journal provides a research, development and evaluation forum for communication between academic teachers, researchers and practitioners in professional and pharmacy education, with an emphasis on new and established teaching and learning methods, new curriculum and syllabus directions, educational outcomes, guidance on structuring courses and assessing achievement, and workforce development. It is a peer-reviewed online open access platform for the dissemination of new ideas in professional pharmacy education and workforce development. Pharmacy Education supports Open Access (OA): free, unrestricted online access to research outputs. Readers are able to access the Journal and individual published articles for free - there are no subscription fees or ''pay per view'' charges. Authors wishing to publish their work in Pharmacy Education do so without incurring any financial costs.